๐ฐ Lars Wegner News
Page 2 - Lars Wegner News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lars Wegner. Real-time updates on events, politics, business and more.
March 7, 2022
COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now
January 26, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
January 26, 2022
Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
November 5, 2021
COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve
October 25, 2021
Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
October 14, 2021
Recognizes achievements in AI-enabled drug discoveryHighlights how Evaxion's platforms help to design novel immunotherapies efficiently COPENHAGEN, Denmark, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Evaxion
October 14, 2021
Investegate announcements from Evaxion Biotech, Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award
April 20, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to ... Evaxion BiotechApril 20, 2021 GMT COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (โEvaxionโ or the โCompanyโ), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bac...
April 6, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update Evaxion BiotechApril 6, 2021 GMT Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31...
February 17, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.